For more than two decades, a single one-gram dose of azithromycin was the answer most people got when they tested positive for chlamydia. It was simple, effective enough, and easy to take under observation in a clinic. That guidance has changed. This article explains what azithromycin does, why it was favored for so long, what the newer evidence actually showed, and how the current recommendations for chlamydia, gonorrhea, and related bacterial infections now differ from what many patients still assume to be true.
How Azithromycin Works and Why It Became the Standard
Azithromycin belongs to the macrolide class of antibiotics. It works by binding to the bacterial ribosome's 50S subunit, blocking the machinery bacteria use to build proteins, which stops them from multiplying. It is derived semisynthetically from erythromycin, a compound first isolated in 1949 from a soil sample containing the bacterium Streptomyces erythreus. That such a common, unremarkable organism in the ground beneath our feet could yield a medicine capable of clearing an infection is a small but real reminder of how much order and provision is built into the natural world, waiting to be discovered rather than invented.
What made azithromycin especially attractive for chlamydia specifically was its pharmacology: it concentrates heavily in tissue and persists there for days after a single dose, unlike most antibiotics that need repeated dosing to maintain effective levels in the blood. For a sexually transmitted infection that often causes no symptoms, and for public health programs trying to treat as many people as possible before they are lost to follow-up, a single one-gram dose that could be swallowed in front of a clinician solved a real adherence problem. Since the 1990s, the Centers for Disease Control and Prevention (CDC) listed azithromycin as a first-line, equally preferred option alongside doxycycline (100 mg twice daily for seven days) for urogenital chlamydia.
The Evidence That Changed the Guidance
The shift did not come from a single study but from a body of research over roughly a decade. A randomized controlled trial published in the New England Journal of Medicine in 2015, led by William Geisler and colleagues and funded by the National Institutes of Health, compared azithromycin and doxycycline head-to-head in men with urogenital chlamydia. It found doxycycline modestly but measurably more effective at achieving microbiologic cure, though the difference for straightforward urogenital infection was small.
The more decisive evidence concerned rectal chlamydia, which is common in men who have sex with men and also occurs in women, sometimes without any genital infection being detected. Multiple observational studies and a meta-analysis published in the mid-2010s found that azithromycin cured rectal chlamydia in roughly three-quarters to four-fifths of cases, while doxycycline cured well over 95 percent. That gap is large enough to matter clinically, because untreated rectal infection can persist, cause ongoing transmission, and in some cases seed re-infection of the genital tract.
Based on this accumulating evidence, the CDC's 2021 Sexually Transmitted Infections Treatment Guidelines removed azithromycin as a co-equal option for chlamydia in most circumstances and named doxycycline the preferred treatment for genital, rectal, and pharyngeal infection alike. This is a case where the guidance changed because the research demanded it, not because of fashion or convenience. It is worth saying plainly: the older single-dose approach was reasonable given what was known at the time, and it is still an available option in specific situations, discussed below.
What Current Guidance Actually Recommends
As of the CDC's most recent treatment guidance, the following distinctions matter:
- Non-pregnant adults and adolescents with chlamydia: doxycycline 100 mg twice daily for seven days is the preferred regimen for infection at any anatomic site.
- Pregnant women: doxycycline is not recommended in pregnancy because of its known effects on fetal bone growth and developing teeth. Azithromycin 1 g as a single oral dose remains the recommended treatment for chlamydia in pregnancy, and this is an important exception, not an oversight. Protecting the pregnancy while still clearing a maternal infection that can otherwise be passed to a newborn during delivery, causing eye infection or pneumonia in the infant, is exactly the kind of situation where the safer-for-the-baby option is chosen even if it is marginally less effective for the mother.
- Partner treatment: when a partner cannot be easily brought in for testing, expedited partner therapy is often used, and azithromycin's single-dose convenience still has a practical role there, though clinicians increasingly weigh doxycycline even in that setting.
- Retesting: because reinfection is common, guidelines recommend retesting around three months after treatment regardless of which drug was used and regardless of whether the partner was treated.
None of this means azithromycin has been abandoned. It means it has been repositioned to the situations where its particular strengths, principally the ability to give a full course in one observed dose, genuinely outweigh its somewhat lower cure rate.
Gonorrhea: A Different Story, Driven by Resistance
Azithromycin's story with gonorrhea has moved in the same direction for a different reason. For years, the standard approach to gonorrhea was dual therapy: an injection of ceftriaxone plus a dose of azithromycin, partly to treat possible co-existing chlamydia and partly because combining two drugs was thought to slow the development of resistance in Neisseria gonorrhoeae, a bacterium with a well-documented history of adapting to whatever antibiotic is thrown at it.
That strategy ran into a problem: gonorrhea isolates with reduced susceptibility to azithromycin began rising in surveillance data collected by the CDC's Gonococcal Isolate Surveillance Project. Adding a drug that is losing its effectiveness does not protect against resistance; it can accelerate it, because bacteria exposed to a failing antibiotic under selective pressure are more likely to develop and spread resistance genes. In response, the CDC's 2020 update to gonorrhea treatment guidance dropped azithromycin from routine dual therapy and now recommends a single dose of ceftriaxone 500 mg intramuscularly (increased from the earlier 250 mg dose) as monotherapy for uncomplicated gonorrhea, with doxycycline added only if chlamydia has not been ruled out. Azithromycin is not currently a recommended primary treatment for gonorrhea in the United States.
Other Bacterial STIs and Practical Safety Considerations
Azithromycin still has recognized roles elsewhere in sexual health:
- Chancroid, caused by Haemophilus ducreyi and rare in the United States, can be treated with a single 1 g oral dose of azithromycin, and this remains a current CDC-listed option.
- Lymphogranuloma venereum (a more invasive form of chlamydial infection) is preferentially treated with three weeks of doxycycline; azithromycin given weekly for three weeks is listed as an alternative where doxycycline cannot be used, though supporting data are more limited.
- Mycoplasma genitalium, an increasingly recognized cause of urethritis and cervicitis, illustrates the resistance problem sharply. Studies from Australia, Europe, and the United States over the past decade have found that a substantial proportion of M. genitalium strains already carry mutations conferring macrolide resistance, sometimes exceeding 50 percent of tested samples in some populations. Because of this, current guidance recommends resistance-guided therapy where possible, or a sequential approach using doxycycline first to reduce bacterial load before azithromycin or, where resistance is confirmed or suspected, moxifloxacin. Azithromycin alone is no longer considered reliable first-line therapy for this infection in many settings.
On safety, azithromycin is generally well tolerated, with gastrointestinal upset being the most common complaint. The FDA issued a warning in 2013 after a study by Wayne Ray and colleagues at Vanderbilt University, published in the New England Journal of Medicine, found a small but statistically real increase in cardiovascular death associated with a five-day azithromycin course compared with no antibiotic or with amoxicillin, concentrated almost entirely among patients who already had significant underlying cardiovascular risk. For most healthy adults being treated for an STI, this risk is not a meaningful barrier, but it is a legitimate reason for a physician to ask about heart rhythm problems or other QT-prolonging medications before prescribing it, and for patients to mention their full medical history rather than assume any antibiotic is interchangeable with any other.
None of these medications treat every STI. Trichomoniasis, for instance, requires metronidazole or tinidazole, not a macrolide, and syphilis still requires penicillin in almost all circumstances. A correct diagnosis, established through proper testing rather than guesswork, remains the necessary first step before any of this guidance is useful.
The Larger Point: Informed Decisions, Not Default Prescriptions
The movement of azithromycin from default chlamydia treatment to a more selectively used option is a healthy example of medicine correcting itself as better trials and surveillance data accumulate. It also underscores something worth remembering about any single-dose or convenience-driven treatment: convenience is a real and legitimate consideration, particularly for people who face genuine barriers to completing a week of twice-daily dosing, but it should never quietly substitute for asking what actually cures the infection most reliably at the site where it lives. Patients are well served by asking their physician directly which drug is being recommended, why, and whether their specific situation, pregnancy, a rectal or pharyngeal exposure, or a partner who cannot be treated, changes the calculation. That conversation, not a one-size-fits-all prescription, is where good stewardship of one's own health actually happens.
Key takeaway: Doxycycline, not azithromycin, is now the preferred first-line treatment for chlamydia in most adults, while azithromycin remains the right choice in pregnancy and in a few other specific circumstances, so patients should confirm with their physician which drug fits their particular case.